Loading stock data…
ROP.SW
CHF 319.40+4.10 (+1.30%)
Market ClosedLast close May 11
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current PriceCHF 319.40
Potential Upside
29.6%
Whystock Fair ValueCHF 413.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean targetCHF 360.76+13.0%
RangeCHF 230.00 – CHF 428.00
Fundamentals
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tum...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
CHF 254.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.64
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
311.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.27%
Volume
Today's trading volume
724,136
Recent News
Zealand Pharma Obesity Trials Shape Future Revenue Potential And Partner Dependence
Zealand Pharma and Roche are advancing obesity drug petrelintide into Phase 3 after positive Phase 2 data on weight loss and tolerability. Boehringer Ingelheim reported strong Phase 3 results from the SYNCHRONIZE-1 trial for survodutide, a GLP-1/glucagon dual agonist licensed from Zealand Pharma. These two clinical milestones highlight Zealand Pharma's role in obesity and metabolic health drug development. For investors tracking CPSE:ZEAL, the stock trades at DKK346.6, with the share price...
GLP-1 battle heats up between Eli Lilly and Novo Nordisk
BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.